10 July 2024
Eden Research
plc
("Eden"
or "the Company")
Director/PDMR
Shareholding
Eden Research plc (AIM: EDEN), the
AIM-quoted company focused on sustainable biopesticides and
plastic-free formulation technologies for use in the global crop
protection, animal health and consumer products industries,
announces that on 10 July 2024, Derek McAllan, Non-Executive
Director, has purchased 323,017 ordinary shares of £0.01 each in
the Company ("Ordinary Shares") at a price of 4.6437 pence per
Ordinary Share.
Following the purchase outlined
above, Derek McAllan's interest in the share capital of the Company
is 323,017 Ordinary Shares, representing 0.06 per cent. of the
Company's issued share capital.
The notification below, made in
accordance with the requirements of the EU Market Abuse Regulation,
provides further detail.
For further information
contact:
Eden
Research plc
|
|
Sean Smith
Alex Abrey
|
www.edenresearch.com
01285 359
555
|
|
|
Cavendish Capital Markets Limited (Nominated advisor and
broker)
|
|
Giles Balleny / George
Lawson (corporate finance)
Charlie Combe (corporate broking)
Michael Johnson (sales)
|
020 7220
0500
|
|
|
Hawthorn Advisors (Financial PR)
|
|
Victoria Ainsworth
|
eden@hawthornadvisors.com
|
Notes to Editors:
Eden Research is the
only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative
biopesticide products and natural microencapsulation technologies
to the global crop protection, animal health and consumer products
industries.
Eden's products are formulated with
terpene active ingredients, based on natural plant defence
metabolites. To date, they have been primarily used on high-value
fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional
pesticides. Eden has three products currently on the
market:
Based on plant-derived active
ingredients, Mevalone® is a foliar biofungicide which
initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops. It is a useful
tool in crop defence programmes and is aligned with the
requirements of integrated pest management programmes. It is
approved for sale in a number of key countries whilst Eden and its
partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.
Cedroz™ is a
bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and
vegetable crops globally. Cedroz is registered for sale on
two continents and Eden's commercial collaborator, Eastman
Chemical, is pursuing registration and commercialisation of this
important new product in numerous countries globally.
Eden's seed treatment
product, Ecovelex™ was developed to safely
tackle crop destruction caused by birds - a major cause of losses
in maize and other crops. Ecovelex works by creating an
unpleasant taste or odour that repels birds, leaving the seeds
safely intact and the birds unaffected and free to find alternative
food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, U.S. and elsewhere, and formulated
using Eden's Sustaine microencapsulation system.
Eden's Sustaine® encapsulation
technology is used to harness the biocidal efficacy of naturally
occurring chemicals produced by plants (terpenes) and can also be
used with both natural and synthetic compounds to enhance their
performance and ease-of-use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres
derived from yeast. It is one of the only viable, proven and
immediately registerable solutions to the microplastics problem in
formulations requiring encapsulation.
Eden was admitted to trading on AIM
on 11 May 2012 and trades under the symbol EDEN. It was
awarded the London Stock Exchange Green Economy Mark in January
2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services
that contribute to the global green economy. Eden derives 100% of
its total annual revenues from sustainable products and
services.
For more information about Eden,
please visit: www.edenresearch.com.
The
Company makes the following disclosures in accordance with article
19(3) of the Market Abuse Regulation:
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
Derek McAllan
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Non-Executive Director
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Eden Research plc
|
b)
|
LEI
|
213800ZWTYTVQQSM3J85
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1 pence
each
GB0001646941
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
c)
|
Price(s) and volume(s)
|
323,017 Ordinary Shares at
4.6437 pence per Ordinary Share
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
e)
|
Date of the transaction
|
10 July 2024
|
f)
|
Place of the transaction
|
London Stock Exchange
|